Results
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
San Diego, October 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the third quarter of fiscal year 2026.
Third quarter 2026 results
4Reported revenue was $1.13 billion for Q3 2026, up 4.2% from Q3 2025.
3Revenue excluding tariff refunds was $1.17 billion, up 4.7% after also excluding the impacts of currency, acquisitions, and the Greater China region (“ROW 1 organic revenue growth”).
GAAP operating margin was 27.0% and non ‑ GAAP operating margin, excluding tariff refunds, was 25.0%.
GAAP diluted EPS was $1.43 and non ‑ GAAP diluted EPS, excluding tariff refunds, was $1.44.
“In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance.
Based on continued momentum, we are raising our full year revenue and earnings guidance,” said Jacob Thaysen, Chief Executive Officer of Illumina.
“As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem.
Together with our customers, we are laying the foundation for AI to transform our understanding of human biology and improve patient outcomes.”
Fiscal year 2026 guidance
For fiscal year 2026 and excluding tariff refunds, Illumina now expects:
6Total revenue of $4.64-$4.66 billion versus prior guidance of $4.60-$4.64 billion.
2Organic revenue growth greater than 4% and ROW organic revenue growth greater than 5%, both unchanged versus prior guidance.
5Non-GAAP operating margin of 23.6% versus prior guidance of 23.4%-23.6%.
Non-GAAP diluted EPS of $5.40-$5.45 versus prior guidance of $5.30-$5.40.
Third quarter results
(a) See tables in “Results of Operations - Non-GAAP” section below for GAAP and non-GAAP reconciliations.
1(b) Excludes the impacts of International Emergency Economic Powers Act (IEEPA) tariff refunds expected to be recovered, consisting primarily of a $79 million benefit recognized as a reduction to cost of revenue in Q3 2026 and a reduction to revenue of $37 million for the portion of tariff refunds that we expect to credit to customers.
1 R OW = rest-of-world, excluding Greater China region due to our inclusion on China’s Unreliable Entities List
Capital expenditures for free cash flow purposes were $41 million for Q3 2026.
7Cash flow provided by operations was $419 million, compared to $284 million in the prior year period.
8Free cash flow (cash flow provided by operations less capital expenditures) was $378 million for the quarter, compared to $253 million in the prior year period.
Depreciation and amortization expense was $71 million for Q3 2026.
At the close of the quarter, the company held $1.34 billion in cash, cash equivalents and short-term investments.
To ensure timely connection, please join at least ten minutes before the scheduled start of the call.
Statement regarding use of non-GAAP financial measures
The company reports non-GAAP results for diluted earnings per share, gross margin, operating margin, and free cash flow, among others, in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.
The company’s financial measures under GAAP include substantial charges such as amortization of acquired intangible assets, among others, that are listed in the reconciliations of GAAP and non-GAAP financial measures included in this press release.
Management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance.
Non-GAAP operating margin and diluted earnings per share are key components of the financial metrics utilized by the company’s board of directors to measure, in part, management’s performance and determine significant elements of management’s compensation.
The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business.
Reconciliations between GAAP and non-GAAP results are presented in this release.
The company provides forward-looking guidance on a non-GAAP basis.
The company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures because it is unable to predict with reasonable certainty the impact of items such as acquisition-related costs, fair value adjustments to contingent consideration, gains and losses from strategic investments, asset impairments, restructuring activities, and the ultimate outcome of pending litigation, among others, without unreasonable effort.
These items are uncertain, inherently difficult to predict, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.
For the same reasons, the company is unable to address the significance of the unavailable information, which could be material to future results.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets.
Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
To learn more, visit www.illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.